8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 15, 2006 (November 14, 2006)

CHEMBIO DIAGNOSTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada	0-30379	88-0425691
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification Number)
	3661 Horseblock Road
	Medford, NY 11763
	(Address of principal executive offices)
	631-924-1135
	(Registrant’s Telephone Number)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 2.02. Results of Operations and Financial Condition

To the extent applicable, the information disclosed under Item 7.01 is incorporated herein by reference.

ITEM 3.02. Unregistered Sales of Equity Securities

On October 31, 2006, Chembio Diagnostics, Inc, (the “Company”) issued to Investor Relations Group, Inc., in payment for consulting services, warrants to purchase 8,334 shares, of the Company’s Common Stock having an exercise price of $0.70 per share and 8,334 shares of the Company’s Common Stock. The warrants are exercisable immediately and expire five years from the date of issue. The Company relied on Section 4(2) of the Securities Act of 1933 as the basis for its exemption from registration of this issuance. The sole investor in the issuance was an accredited investor. 

On November 15, 2006, the Company issued 144,047 shares of common stock as payment of dividends on the Company’s series A preferred stock. No cash was exchanged in this issuance. The Company relied on Section 4(2) of the Securities Act of 1933 as the basis for its exemption from registration of this issuance. The investors in the issuance were accredited investors of the Company.

No commissions or underwriting fees were paid in either of the foregoing issuances.

ITEM 7.01. Regulation FD Disclosures.

On November 14, 2006, the Company issued the press release titled “Chembio Diagnostics Announces Third Quarter Results” included herein as Exhibit 99.1.

On November 14, 2006, the Company issued the press release titled “CORRECTING and REPLACING Chembio Diagnostics Announces Third Quarter Results” included herein as Exhibit 99.2.

ITEM 9.01. Financial Statements and Exhibits

Exhibits.

99.1   Press Release titled “Chembio Diagnostics Announces Third Quarter Results” issued November 14, 2006.

99.2   Press Release titled “CORRECTING and REPLACING Chembio Diagnostics Announces Third Quarter Results” issued November 14, 2006.

In accordance with General Instruction B.2 of Form 8-K, the information disclosed in Items 2.02 and 7.01 of, and Exhibits 99.1 and 99.2 attached to, this Current Report on Form 8-K shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing. This Current Report on Form 8-K does not constitute a determination of whether any information included herein is material.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 15, 2006Chembio Diagnostics, Inc.

By:  /s/ Lawrence A. Siebert

Lawrence A. Siebert

Chief Executive Officer

EX-99.1

Chembio Diagnostics Announces Third Quarter Results

New York, November 14, 2006--- Chembio Diagnostics, Inc. (OTCBB:CEMI) has reported its financial results for the third quarter ended September 30, 2006.

Revenues for the third quarter of 2006 were $1.02 million, an 8% increase over third quarter 2005 revenues of $945,000. The third quarter 2006 net loss attributable to common stockholders was $2.33 million, or $0.21 per share, compared with a net loss attributable to common stockholders of $1.04 million, or $0.13 per share, for the third quarter of 2005.

Revenues for the first nine months of 2006 were $3.89 million, a 51% increase over the $2.58 million in revenues reported during the first nine months of 2005. Net loss attributable to common stockholders for the first nine months of 2006 was $5.61 million, or $0.56 per share, compared to a net loss attributable to common stockholders of $5.63 million, or $0.75 per share, for the first nine months of 2005.

Included in the third quarter increase in revenues was a $230,000 increase in sales of its Chagas tests, which reached $259,000, compared with $28,000 during last year’s third quarter. The increase in Chagas sales was the result of the Company obtaining its first significant order for this product, in the amount of $1.2 million, of which it shipped $950,000 in the first half of 2006 and the balance of $230,000 in the third quarter of 2006.

Significant Developments in the Quarter included the following:

-- Received a purchase order for 990,000 of its SURE CHECK(R) HIV 1/2 rapid tests from the Company's exclusive distributor in Mexico which order was reported on November 6. The tests will be used for the Mexican Ministry of Health program to screen pregnant women. During the next several weeks, a shipment schedule will be finalized with the distributor.

-- Entered into three agreements with Inverness Medical Innovations, Inc., a leader in point of care diagnostics for both consumer and professional markets. Inverness will market Chembio's two FDA approved rapid tests for the detection of antibodies to HIV. Inverness also granted Chembio a license to its lateral flow intellectual property and invested $2 million in the Chembio Series C financing.

-- Completed the initial closing of $4 million on a private placement transaction in the total amount of $8.15 million of Series C 7% Convertible Preferred Stock together with warrants to purchase common stock. The private placement was co-led by Inverness Medical Innovations, Inc. and Crestview Capital Master, LLC, each investing two million dollars. Approximately $600,000 of the private placement resulted from conversion of previously outstanding debt of the Company. The balance of the private financing was closed on October 5, 2006.

-- Settled litigation with StatSure Diagnostic Systems (SDS) regarding SDS' barrel patent and other matters. The settlement combines each company's HIV barrel intellectual property, including an exclusive manufacturing license from StatSure to Chembio of its barrel patent for all HIV applications.

-- Received a new order for 396,000 HIV 1/2 Rapid tests for Nigeria. The United States President's Emergency Plan for Aids Relief (PEPFAR), a five year $15 billion global initiative to combat the HIV/AIDS epidemic, is funding the purchase order, which was placed by the United States Centers for Disease Control. Chembio has received in the last six months orders for more than 700,000 tests funded by PEPFAR for Nigeria

Larry Siebert, Chief Executive Officer of Chembio said, “This was a very strategically productive quarter for Chembio, one in which we raised capital, signed a significant marketing partner and also settled litigation.”

“Importantly, we also continued to experience robust orders of our rapid diagnostic tests abroad, and are now poised to enter the rapidly growing US market with our rapid HIV tests, pending CLIA waiver, which we anticipate is forthcoming. We also see expanding opportunities for other of our rapid tests for infectious disease, as well as the development of new tests using our DPP ™ technology, which we believe will allow us to develop rapid tests using oral fluid and enter into other new product collaborations, Mr. Siebert added.”

“Following the end of the quarter, we shipped $465,000 of HIV tests to Brazil, on an order we had received during the third quarter. Our net sales through the first nine months of 2006 have already exceeded our net sales for all of 2005, and we believe that our net sales in the fourth quarter will be well ahead of last year’s fourth quarter sales,” Mr. Siebert concluded.

Chembio Diagnostics, Inc.
Summary of Results of Operations
	Third Quarter 2006			Third Quarter 2005			First Nine months of 2006			First Nine months of 2005
Total Revenues	$	1,018,190		$	944,712		$	3,893,093		$	2,582,287
Gross Profit		187,371			274,895			1,187,344			811,540
Operating Loss		(1,240,474	)		(839,313	)		(3,615,740	)		(2,351,221	)
Net Loss		(1,573,986	)		(831,982	)		(3,965,076	)		(2,328,634	)
Preferred Dividends		220,909			206,256			641,769			600,495
Accreted Beneficial Conversion to preferred stock		538,650			-			1,101,994			2,698,701
Net Loss Attributable to Common Stockholders		(2,333,455	)		(1,038,238	)		(5,608,839	)		(5,627,830	)
Loss per share	$	(0.21	)	$	(0.13	)	$	(0.56	)	$	(0.75	)

ABOUT CHEMBIO

Chembio Diagnostics, Inc., a developer and manufacturer of rapid diagnostic tests for infectious diseases, is on the frontlines of the global battle against the AIDS pandemic. The Company has received marketing approval from the FDA for its SURE CHECK® HIV 1/2 and HIV 1/2 STAT-PAK™ rapid tests. The Company also manufactures rapid tests for veterinary Tuberculosis and Chagas Disease, and has developed a patent-pending technology, the Dual Path Platform (DPP™), for its next generation HIV and other rapid tests. For additional information please visit www.chembio.com.

FORWARD-LOOKING STATEMENTS

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only, as the Company has not completed the preparation of its financial statements for those periods, nor has its auditor completed the audit of those results. Actual revenue may differ materially from those anticipated in this press release. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing, to obtain regulatory approvals in a timely manner, and the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

Contact:

The Investor Relations Group 212-825-3210

Investors: James Carbonara

Media: Susan Morgenbesser

EX-99.2

CORRECTING and REPLACING

Chembio Diagnostics Announces Third Quarter Results

NEW YORK--(BUSINESS WIRE)--In the financial table, the Accreted Beneficial Conversion to preferred stock for Third Quarter 2006 should read: 538,560 (sted 538,650), and the Accreted Beneficial Conversion to preferred stock for First Nine months of 2006 should read: 1,001,994 (sted 1,101,994).

The corrected release reads:

Chembio Diagnostics Announces Third Quarter Results

New York, November 14, 2006--- Chembio Diagnostics, Inc. (OTCBB:CEMI) has reported its financial results for the third quarter ended September 30, 2006.

Revenues for the third quarter of 2006 were $1.02 million, an 8% increase over third quarter 2005 revenues of $945,000. The third quarter 2006 net loss attributable to common stockholders was $2.33 million, or $0.21 per share, compared with a net loss attributable to common stockholders of $1.04 million, or $0.13 per share, for the third quarter of 2005.

Revenues for the first nine months of 2006 were $3.89 million, a 51% increase over the $2.58 million in revenues reported during the first nine months of 2005. Net loss attributable to common stockholders for the first nine months of 2006 was $5.61 million, or $0.56 per share, compared to a net loss attributable to common stockholders of $5.63 million, or $0.75 per share, for the first nine months of 2005.

Included in the third quarter increase in revenues was a $230,000 increase in sales of its Chagas tests, which reached $259,000, compared with $28,000 during last year’s third quarter. The increase in Chagas sales was the result of the Company obtaining its first significant order for this product, in the amount of $1.2 million, of which it shipped $950,000 in the first half of 2006 and the balance of $230,000 in the third quarter of 2006.

Significant Developments in the Quarter included the following:

-- Received a purchase order for 990,000 of its SURE CHECK(R) HIV 1/2 rapid tests from the Company's exclusive distributor in Mexico which order was reported on November 6. The tests will be used for the Mexican Ministry of Health program to screen pregnant women. During the next several weeks, a shipment schedule will be finalized with the distributor.

-- Entered into three agreements with Inverness Medical Innovations, Inc., a leader in point of care diagnostics for both consumer and professional markets. Inverness will market Chembio's two FDA approved rapid tests for the detection of antibodies to HIV. Inverness also granted Chembio a license to its lateral flow intellectual property and invested $2 million in the Chembio Series C financing.

-- Completed the initial closing of $4 million on a private placement transaction in the total amount of $8.15 million of Series C 7% Convertible Preferred Stock together with warrants to purchase common stock. The private placement was co-led by Inverness Medical Innovations, Inc. and Crestview Capital Master, LLC, each investing two million dollars. Approximately $600,000 of the private placement resulted from conversion of previously outstanding debt of the Company. The balance of the private financing was closed on October 5, 2006.

-- Settled litigation with StatSure Diagnostic Systems (SDS) regarding SDS' barrel patent and other matters. The settlement combines each company's HIV barrel intellectual property, including an exclusive manufacturing license from StatSure to Chembio of its barrel patent for all HIV applications.

-- Received a new order for 396,000 HIV 1/2 Rapid tests for Nigeria. The United States President's Emergency Plan for Aids Relief (PEPFAR), a five year $15 billion global initiative to combat the HIV/AIDS epidemic, is funding the purchase order, which was placed by the United States Centers for Disease Control. Chembio has received in the last six months orders for more than 700,000 tests funded by PEPFAR for Nigeria

Larry Siebert, Chief Executive Officer of Chembio said, “This was a very strategically productive quarter for Chembio, one in which we raised capital, signed a significant marketing partner and also settled litigation.”

“Importantly, we also continued to experience robust orders of our rapid diagnostic tests abroad, and are now poised to enter the rapidly growing US market with our rapid HIV tests, pending CLIA waiver, which we anticipate is forthcoming. We also see expanding opportunities for other of our rapid tests for infectious disease, as well as the development of new tests using our DPP ™ technology, which we believe will allow us to develop rapid tests using oral fluid and enter into other new product collaborations, Mr. Siebert added.”

“Following the end of the quarter, we shipped $465,000 of HIV tests to Brazil, on an order we had received during the third quarter. Our net sales through the first nine months of 2006 have already exceeded our net sales for all of 2005, and we believe that our net sales in the fourth quarter will be well ahead of last year’s fourth quarter sales,” Mr. Siebert concluded.

Chembio Diagnostics, Inc.
Summary of Results of Operations
	Third Quarter 2006			Third Quarter 2005			First Nine months of 2006			First Nine months of 2005
Total Revenues	$	1,018,190		$	944,712		$	3,893,093		$	2,582,287
Gross Profit		187,371			274,895			1,187,344			811,540
Operating Loss		(1,240,474	)		(839,313	)		(3,615,740	)		(2,351,221	)
Net Loss		(1,573,986	)		(831,982	)		(3,965,076	)		(2,328,634	)
Preferred Dividends		220,909			206,256			641,769			600,495
Accreted Beneficial Conversion to preferred stock		538,560			-			1,001,994			2,698,701
Net Loss Attributable to Common Stockholders		(2,333,455	)		(1,038,238	)		(5,608,839	)		(5,627,830	)
Loss per share	$	(0.21)		$	(0.13	)	$	(0.56	)	$	(0.75	)

ABOUT CHEMBIO

Chembio Diagnostics, Inc., a developer and manufacturer of rapid diagnostic tests for infectious diseases, is on the frontlines of the global battle against the AIDS pandemic. The Company has received marketing approval from the FDA for its SURE CHECK® HIV 1/2 and HIV 1/2 STAT-PAK™ rapid tests. The Company also manufactures rapid tests for veterinary Tuberculosis and Chagas Disease, and has developed a patent-pending technology, the Dual Path Platform (DPP™), for its next generation HIV and other rapid tests. For additional information please visit www.chembio.com.

FORWARD-LOOKING STATEMENTS

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only, as the Company has not completed the preparation of its financial statements for those periods, nor has its auditor completed the audit of those results. Actual revenue may differ materially from those anticipated in this press release. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing, to obtain regulatory approvals in a timely manner, and the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

Contact:

The Investor Relations Group 212-825-3210

Investors: James Carbonara

Media: Susan Morgenbesser